The likely collapse of AbbVie’s $54 billion agreement to buy Shire leaves two global drug companies in need of new, independent courses and investors and Wall Street bankers smarting from losses and fees they won’t collect.

Since AbbVie said late Wednesday that tax-system changes prompted its board to withdraw its support for the deal, fallout from the decision has come into sharper focus.